Adjuvant taxane + anthracycline therapy in HR+/HER2- BC with high RS values

(1:27)

PATHFINDER: ipatasertib with non-taxane chemotherapy in patients with aTNBC

(1:20)

EAZ171: assessing the best taxane for peripheral neuropathy reduction in breast cancer

(1:27)

Adjuvant I/O in TNBC

(9:14)

Nab-Paclitaxel as Neoajuvant Therapy for Breast Cancer

(1:45)

Dr. Markman on Taxane-Induced Neuropathy Biomarkers

(1:4)

CONTESSA: Oral Taxane Meets Primary Endpoint

(2:21)

Adding atezolizumab to adjuvant chemotherapy for stage II and III triple-negative breast cancer ...

(4:49)

EAZ171: taxane-induced peripheral neuropathy in Black women with breast cancer

(2:25)

Advantages of Oral Taxanes in mBC

(9:20)

Taxanes in Cancer Treatment

(2:52)

GS2-06: \

(10:29)

MA.31 Trial: Taxane With Lapatinib or Trastuzumab in First-line Metastatic Breast Cancer

(2:39)

Triple Negative Breast Cancer: Predictive and Prognostic Biomarkers for Neo/Adjuvant Therapy

(27:3)

Debate: The taxane of choice for managing NSCLC is nab-paclitaxel - Agree

(9:39)

Dr Waks on Anthracycline- vs Taxane-Based Therapy in HER2+ Breast Cancer

(1:42)

Neelima Denduluri, MD -- Treatment of Triple Negative Breast Cancer

(33:30)

Investigating anthracycline, taxane and trastuzumab-based neoadjuvant chemotherapy in HER2+ eBC

(1:55)

Advantages of Oral Taxanes in mBC

(9:20)

Adjuvant docetaxel fails after radical prostatectomy for high risk prostate cancer

(7:13)